ArticleVeterinary sciences2026
Formulation-Level Tolerability of Repeated Drinking-Water Administration of a Commercial Multi-Component Bacteriophage Product in Ross 308 Broiler Chickens: A Pilot 27-Day Dose-Escalation Study.
Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacteriophage-based interventions are increasingly considered antibiotic-sparing tools in poultry production, but target-animal tolerability should be documented before efficacy-oriented field application.
methodsThis pilot study evaluated the formulation-level tolerability of the repeated drinking-water administration of Fagovet, a commercial multi-component bacteriophage product, in Ross 308 broiler chickens under non-challenged conditions. According to the manufacturer's product documentation, the formulation contains a declared mixture of 23 bacteriophages at a concentration of not less than 1 × 10
resultsBody-weight gain did not differ from controls at 1× (ratio 0.99; 95% CI 0.88-1.10;
conclusionsRepeated drinking-water administration of the tested commercial formulation was well tolerated under the conditions of this pilot study. Because individual phage components, genomic safety, actual PFU-based exposure, and drinking-water stability were not independently characterized, the findings apply to the administered formulation and should not be interpreted as a component-level safety or quantitative phage dose-response assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.